The origins of Moderna trace back to 2005, when Hungarian biochemist Katalin Karikó and American immunologist Drew Weissman at the University of Pennsylvania published foundational research demonstrating that modified mRNA could evade the body's inflammatory response, solving the key obstacle that had prevented mRNA therapeutics from reaching clinical application. In 2009, Harvard Medical School biologist Derrick Rossi successfully used this modified mRNA technology to reprogram adult human fibroblasts into induced pluripotent stem cells, a breakthrough that attracted the attention of Timothy Springer, a Harvard immunologist and successful entrepreneur. Springer introduced Rossi to Robert Langer, a pioneering biomedical engineer at MIT and one of the most cited engineers in history, who recognized the transformative potential of mRNA for drug delivery. Within days, Langer enlisted Noubar Afeyan, CEO of Flagship Pioneering, a Cambridge venture capital firm, to fund a startup. In September 2010, Afeyan, Langer, Rossi, Springer, and Harvard cardiovascular scientist Kenneth Chien founded Moderna Therapeutics, taking the name from a combination of modified and RNA. The company's founding vision was to create a digital biotech platform that would use mRNA to instruct human cells to produce therapeutic proteins, treating diseases at the genetic level without altering the genome. Flagship Pioneering provided initial seed funding and incubated the company within its venture lab, with Stéphane Bancel, a former bioMérieux executive, joining as founding CEO in 2011. Moderna operated in stealth mode for its first two years, building its platform and filing foundational patents, before emerging publicly in 2012 with a $40 million Series A financing. The early years were characterized by skepticism from the scientific community, as mRNA had never been successfully developed into an approved medicine, and many investors doubted the technology could overcome delivery, stability, and immunogenicity challenges. Moderna addressed these concerns through rapid iteration of its lipid nanoparticle formulation and mRNA modification chemistry, building a proprietary platform that would eventually prove its value during the COVID-19 pandemic. The company's early pipeline focused on rare diseases, including methylmalonic acidemia and propionic acidemia, where mRNA could provide missing enzymes, but these programs remained in early development as the company pivoted to infectious disease vaccines in 2018. The 2018 strategic pivot, which prioritized respiratory vaccines and latent viruses, was driven by the realization that mRNA's speed of development made it ideal for responding to emerging pathogens, a insight that would prove prescient when SARS-CoV-2 emerged in late 2019. The company's early scientific team, which included researchers from Harvard, MIT, and the University of Pennsylvania, brought diverse expertise in mRNA chemistry, lipid formulation, immunology, and manufacturing engineering. This interdisciplinary team was critical to solving the multiple technical challenges that had prevented mRNA from reaching clinical application, including mRNA stability, immunogenicity, delivery efficiency, and manufacturing scale. The company's first laboratory, located in Kendall Square, Cambridge, was a modest space that housed a small team of scientists working to optimize mRNA modification chemistry and lipid nanoparticle formulations. The company's early experiments, which involved testing hundreds of lipid formulations and nucleotide modifications, produced the proprietary platform that would eventually enable Spikevax. The company's decision to prioritize broad platform development over narrow product focus, which was controversial among some investors who preferred faster paths to revenue, proved critical to the pandemic response. The platform's flexibility, which allowed rapid switching between different mRNA sequences, was the key advantage that enabled the 63-day development timeline for mRNA-1273. The early struggles with investor skepticism and scientific criticism, while painful, forced the company to build robust data packages and manufacturing capabilities that would prove essential during the pandemic. The founding story of Moderna is therefore a case study in platform biotechnology development, where long-term investment in fundamental technology, combined with visionary leadership and strategic partnerships, can produce extraordinary results when external events create opportunity.